Onco Actu du 27 octobre 2016

	3.1 Tabac
Exclusive: India's tobacco industry, government face off ahead of WHO conference [Reuters] India's $11 billion tobacco industry has urged the government to take a softer line on tobacco control efforts when it hosts a World Health Organization conference in New Delhi next month, but officials say the government will not bow to "pressure tactics".
	3.3 Prévention - Vaccins
Gardasil leads the charge as Merck vaccines soar in Q3 [FiercePharma] Gardasil beat analyst estimates by more than $200 million.
	4.2 Dép., diag. & prono. - Génome
23andMe Has Abandoned The Genetic Testing Tech Its Competition Is Banking On [BuzzFeed] Other companies are starting to sell next-generation sequencing-based tests to the public, and the FDA considers it to be the next chapter in genetic testing. But in August, 23andMe let go of its team of roughly a half-dozen scientists who were working on next-generation sequencing in a lab in Salt Lake City, Utah.
	5.2 Pharma
Myriad's BRACAnalysis CDx® Test Identifies Patients with Ovarian Cancer Who Would Benefit from Second-Line Maintenance Treatment with Olaparib [Myriad] The BRACAnalysis CDx test was included in the SOLO2 study (NCT01874353) as a diagnostic with olaparib, an oral PARP inhibitor being developed by AstraZeneca.
Lynparza Phase III SOLO-2 trial shows significant progression-free survival benefit [AstraZeneca] Today’s positive results follow the Fast Track Designation for Lynparza by the US FDA earlier this year, in patients with a BRCA mutation who have platinum-sensitive, relapsed ovarian cancer.
AstraZeneca celebrates a PhIII PARP success for Lynparza, putting pressure on Tesaro rival [EndPoints] Investigators tested the drug as a maintenance monotherapy compared with placebo in patients with platinum-sensitive relapsed or recurrent BRCA-mutated (BRCAm) ovarian cancer. And that’s all you’re going to get right now, as investigators gather their data for an upcoming scientific conference.
AstraZeneca Is Now a Competitive Threat to Tesaro in Ovarian Cancer Maintenance Therapy [The Street] Lynparza belongs to a closely followed class of cancer drugs known as PARP inhibitors. Wednesday's positive study results, if confirmed, position Lynparza for expanded U.S. approval as a maintenance therapy in ovarian cancer.
	5.2.2 Pharma - Fusions & Acquisitions
Novartis Looks at Up to $5 Billion Deals in Cancer, Generics [Bloomberg] Big transactions are a lower priority for Novartis because of the company’s pipeline of a dozen potential blockbusters that may reach the market over the next three years, the CEO said.
	5.4 Traitements - Economie
Off-Label Drug Coverage in Oncology [ESMO] They concluded that the current compendia-based approach for coverage decisions in oncology has lacked oversight and is not suitable for making safe recommendations or coverage decisions for cancer drugs. Given the clear limitations of this outdated system, a different model is warranted.
	6. Lutte contre les cancers
The plight of young scientists [Nature] A special issue explores how the research enterprise keeps early-career scientists from pursuing the most important work, and what can be done to help.
	6.1 Observation
Cancer survivors take more psych meds than other people [Reuters] Almost 14 percent of cancer survivors took antidepressants, compared to 8 percent of the other adults in the study, researchers report in the Journal of Clinical Oncology.
	6.11 Patients
Why is it so hard for patients with metastatic cancer to participate in clinical trials? [Philly] I am not surprised at the oft-quoted estimate that only about three to five percent of cancer patients participate in clinical trials. And I had to restrain myself from laughing out loud the first time I heard a doctor baffled about why it was hard to find trial patients.
	6.8 Communication
New Online Tool Offers Essential Tools for Cancer Survivors [ACS] “With Springboard Beyond Cancer, we want to empower cancer survivors by giving them the information they need to help identify issues, set goals, and create a plan to more smoothly navigate the cancer journey and take control of their health.”
Increasing Awareness of Breast Cancer Health Disparities [AACR] Complex and interrelated factors contribute to breast cancer health disparities in the United States. As a result, a multifaceted approach is needed to address the challenge. One facet is to raise awareness of the issue.